05:32 PM EDT, 04/24/2024 (MT Newswires) -- Viking Therapeutics ( VKTX ) reported a Q1 net loss late Wednesday of $0.26 per diluted share, compared with a loss of $0.25 per share a year earlier.

Analysts polled by Capital IQ expected a loss of $0.28.

No revenue was reported in the quarter ended March 31, as expected.

The company said it held $963 million in cash, cash equivalents, and marketable securities at the end of Q1, supporting advancement of its pipeline through clinical milestones.

Viking Therapeutics ( VKTX ) shares fell 3.3% in after-hours activity.

Price: 62.90, Change: -2.17, Percent Change: -3.33